Intimation about the resignation of Head of department-Injection is attached
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mercury Laboratories Ltd has informed the stock exchange that Mr. Jagdish Patil, Head of the Department (Injectable Production) and a designated Senior Management Personnel (SMP), has resigned from the company. His resignation is effective from the close of business hours on April 16, 2025. The reason cited is personal career advancement and better opportunities, with no other material reasons disclosed. The company has filed this intimation under SEBI LODR Regulation 30, along with the required Annexure-A details and the resignation letter as Annexure-B. There is no mention of a successor or replacement being appointed at this stage.
This is a routine senior-level departure from a manufacturing-critical function (injectable production). For shareholders, the resignation of a production head could raise short-term operational continuity questions, though the company has not flagged any disruption. The stock price impact is likely negligible unless production is materially affected.